Optimizing Infusion Therapy Prior Authorizations with Surescripts Integration
Streamline prior authorization workflows for specialty drugs in Infusion Therapy with robust Surescripts integration, reducing administrative burden and accelerating patient access to care.
The complexities of Infusion Therapy, particularly for specialty drugs, demand an efficient prior authorization process. Revenue cycle directors and prior authorization coordinators face significant challenges navigating payer-specific requirements, site-of-service reviews, and the high cost of delays. Klivira's platform, leveraging Surescripts ePA capabilities, offers a targeted solution to these critical pain points.
The Role of Surescripts ePA in Infusion Therapy Prior Authorization
Surescripts integration is foundational for managing specialty drug prior authorizations, which are prevalent in Infusion Therapy. This platform facilitates electronic prior authorization (ePA) and eligibility checks, connecting providers to a vast network of payers. For infusion centers, this means a more direct and standardized pathway for submitting the X12 278 transaction equivalent and receiving responses, moving away from manual submission methods.
Navigating Site-of-Service Reviews and RBM Routing
A critical dimension of Infusion Therapy prior authorization is the site-of-service review, determining whether care is approved for home, outpatient, or hospital outpatient department (HOPD) settings. Klivira's Surescripts integration supports rules-based medical necessity (RBM) routing, which helps direct the PA request to the correct payer pathway based on the proposed site, drug, and patient-specific criteria, minimizing initial processing errors.
Essential Clinical Documentation for Infusion Therapy PAs
- Patient history and detailed diagnosis (ICD-10 codes)
- Proposed CPT codes for the infusion drug and administration
- Documentation of previous treatment failures or contraindications to alternative therapies
- Relevant lab results (e.g., biomarker tests, organ function panels)
- Imaging reports supporting medical necessity
- Physician's notes clearly detailing the medical necessity and treatment plan
- Justification for the requested site-of-service, if applicable
Common Denial Themes Specific to Infusion Therapy PAs
Denials for Infusion Therapy prior authorizations often stem from specific issues. These include insufficient documentation of medical necessity, lack of clear justification for the chosen site-of-service, and non-adherence to payer-specific formulary requirements for specialty drugs. Klivira's platform helps mitigate these by ensuring comprehensive data submission and real-time eligibility checks via Surescripts ePA.
Accelerating Peer-to-Peer Review Cadence
When a prior authorization requires a peer-to-peer (P2P) review, timely and complete clinical data is paramount. By leveraging Surescripts integration for initial ePA submission, Klivira ensures that all necessary documentation is systematically compiled and readily accessible. This comprehensive preparation can either reduce the frequency of P2P requests or significantly streamline the discussion when a P2P is unavoidable, preventing extended delays in patient care.
Klivira's Approach to Infusion Therapy Surescripts Integration
Klivira integrates Surescripts ePA and eligibility platforms directly into your existing EMR workflows, often utilizing SMART on FHIR standards for seamless data exchange. This integration automates the submission of Infusion Therapy prior authorization requests, provides real-time status updates, and flags potential issues before submission. This proactive approach ensures that complex specialty drug authorizations are managed efficiently, reducing administrative burden and improving turnaround times.
Frequently asked questions
How does Surescripts integration specifically benefit Infusion Therapy prior authorizations?
Surescripts integration provides a standardized electronic pathway for submitting specialty drug prior authorizations common in infusion therapy. It automates eligibility checks and ePA submissions, connecting directly with payers to streamline the initial request and response process, significantly reducing manual effort and potential errors.
What is 'site-of-service review' in the context of infusion therapy, and how does Klivira address it?
Site-of-service review determines the approved location for infusion (e.g., home, outpatient clinic). Klivira's platform, through Surescripts integration, helps ensure that site-specific documentation and medical necessity are accurately captured and submitted, aligning with payer RBM routing rules to minimize denials related to inappropriate care settings.
What common CPT codes are typically associated with Infusion Therapy PAs?
Infusion Therapy PAs often involve CPT codes for drug administration (e.g., 96365-96379 series) and specific drug codes (J-codes). Klivira's system helps ensure that these codes are accurately linked to the corresponding clinical documentation and payer requirements during the ePA submission process.
How does Klivira's platform help with RBM routing for infusion therapy?
Klivira's platform leverages Surescripts data to inform RBM routing, which is critical for infusion therapy. By understanding payer-specific rules for medical necessity and site-of-service, the system guides the PA request to the appropriate pathway, ensuring that the correct documentation and criteria are met for each unique infusion scenario.
Can Surescripts integration help with specialty drug formulary checks for infusion?
Yes, Surescripts ePA capabilities often include access to formulary and benefit information, which is crucial for specialty drugs used in infusion therapy. Klivira integrates this data to provide real-time insights into whether a prescribed drug is on-formulary, helping to prevent denials related to non-covered medications.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo